SpringerLink
Log in

Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Patients with myelodysplastic syndromes (MDS) often show elevated serum ferritin levels at diagnosis, probably caused by increased intestinal iron uptake attributable to ineffective erythropoiesis. Many patients also develop transfusional iron overload. Hepcidin, a pivotal regulator of iron homeostasis, controls iron uptake in the duodenum as well as iron release from macrophages and is potentially involved in iron distribution to different organs. We measured serum hepcidin, together with other laboratory parameters related to iron metabolism and hematopoiesis (ferritin, transferrin, transferrin saturation, soluble transferrin receptor, erythropoietin, and hemoglobin), and C-reactive protein as marker of inflammation, in 89 MDS patients. Hepcidin levels were measured with two different competitive ELISAs: (a) EIA-4705 as described by Schwarz et al. (J Gastroenterol 46:648–656; 2011) and (b) Hepcidin 25 bioactive ELISA (EIA-5258), which was develop by DRG Diagnostics, Marburg, in 2012. Median hepcidin levels with EIA-5258 were as follows: entire cohort 17.5 ng/ml (n = 89), RA/RARS 5.9 ng/ml (n = 5), RCMD 17.8 ng/ml (n = 38), RS-RCMD 8.7 ng/ml (n = 7), RAEB I/II 29.1 ng/ml (n = 22), CMML I/II 16.9 ng/ml (n = 10), and MDS with del(5q) 26.3 ng/ml (n = 7). Hepcidin levels of the RA/RARS patients were significantly lower than in the other groups except RS-RCMD. RS-RCMD had significantly lower levels than RAEB and 5q− patients. There was a positive correlation between hepcidin levels and serum ferritin and transferrin saturation, and a negative correlation between hepcidin and hemoglobin and transferrin. Malcovati et al. (Blood 112:2676a, 2008), Santini et al. (PLoS One 6:e23109, 2011), and Ambaglio et al. (Haematologica 98:420–423, 2013), using mass spectrometry, reported similar results. We further assessed transfusional status and could show that patients who had been transfused have significantly higher hepcidin levels (median 33.3 versus 8.8 ng/ml (p < 0.001)). A dichotomized hepcidin level correlated with worse survival. EIA-4705 as described by Schwarz showed no correlation with markers of iron metabolism. Measurement of serum hepcidin with an improved ELISA yield results that correlate with other parameters of iron metabolism as well as survival and transfusion needs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gattermann N, Rachmilewitz EA (2011) Iron overload in MDS—pathophysiology, diagnosis, and complications. Ann Hematol 90(1):1–10. doi:10.1007/s00277-010-1091-1

    PubMed  CAS  Google Scholar 

  2. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480(2–3):147–150

    Article  PubMed  CAS  Google Scholar 

  3. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276(11):7806–7810. doi:10.1074/jbc.M008922200

    Article  PubMed  CAS  Google Scholar 

  4. Ganz T, Nemeth E (2006) Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290(2):G199–G203. doi:10.1152/ajpgi.00412.2005

    Article  PubMed  CAS  Google Scholar 

  5. Kemna EH, Tjalsma H, Podust VN, Swinkels DW (2007) Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53(4):620–628. doi:10.1373/clinchem.2006.079186

    Article  PubMed  CAS  Google Scholar 

  6. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW (2009) Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 94(12):1748–1752. doi:10.3324/haematol.2009.010322

    Article  PubMed  CAS  Google Scholar 

  7. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101(7):2461–2463. doi:10.1182/blood-2002-10-3235

    Article  PubMed  CAS  Google Scholar 

  8. Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102(3):783–788. doi:10.1182/blood-2003-03-0672

    Article  PubMed  CAS  Google Scholar 

  9. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951. doi:10.1182/blood-2009-03-209262

    Article  PubMed  CAS  Google Scholar 

  10. Schwarz P, Strnad P, von Figura G, Janetzko A, Krayenbuhl P, Adler G, Kulaksiz H (2011) A novel monoclonal antibody immunoassay for the detection of human serum hepcidin. J Gastroenterol 46(5):648–656. doi:10.1007/s00535-010-0344-z

    Article  PubMed  CAS  Google Scholar 

  11. Racchi O, Cangemi G, Montanaro F, Del Corso L, Molinari E, Arboscello EBE, Gatti C, Bruzzone A, Mencoboni M, Ghio R (2011) Serum hepcidin in patients with myelodysplastic syndrome and primary myelofibrosis. Leuk Res 35(S1):S151–S153

    Article  Google Scholar 

  12. Malcovati L, Della Porta MG, Laarakkers CM, Galli A, Albertini R, Maffioli M, Am–baglio I, Travaglino E, Invernizzi R, Moratti R, Swinkels DW, Cazzola M (2008) Erythroid activity, transfusion iron overload, and hepcidin levels in patients with myelodysplastic syndrome. Blood 112: 2676a (ASH annual meeting abstracts)

  13. Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, Cortelezzi A, Corbella M, Bosi A, Reda G, Olivieri O, Cappellini MD (2011) Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One 6(8):e23109. doi:10.1371/journal.pone.0023109

    Article  PubMed  CAS  Google Scholar 

  14. Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Galli A, Da Via MC, Bono E, Ubezio M, Travaglino E, Albertini R, Campbell PJ, Swinkels DW, Cazzola M (2013) Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica 98(3):420–423. doi:10.3324/haematol.2012.077446

    Article  PubMed  CAS  Google Scholar 

  15. Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, Rachmilewitz EA (2008) Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 142(4):669–671. doi:10.1111/j.1365-2141.2008.07225.x

    Article  PubMed  Google Scholar 

  16. Murphy PT, Mitra S, Gleeson M, Desmond R, Swinkels DW (2009) Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 144(3):451–452. doi:10.1111/j.1365-2141.2008.07455.x

    Article  PubMed  CAS  Google Scholar 

  17. Huang X, Fung ET, Yip C, Zeleniuch-Jacquotte A (2008) Serum prohepcidin is associated with soluble transferrin receptor-1 but not ferritin in healthy post-menopausal women. Blood Cells Mol Dis 41(3):265–269. doi:10.1016/j.bcmd.2008.06.009

    Article  PubMed  CAS  Google Scholar 

  18. El Husseiny NM, Matter MM, Sabry RM, Amin IS (2010) Serum prohepcidin level in myelodysplasia. Scand J Clin Lab Invest 70(5):343–346. doi:10.3109/00365513.2010.488700

    Article  PubMed  Google Scholar 

  19. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110(7):1037–1044. doi:10.1172/JCI15686

    PubMed  CAS  Google Scholar 

  20. Ganz T, Nemeth E (2011) The hepcidin–ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011:538–542. doi:10.1182/asheducation-2011.1.538

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Barbara Hildebrandt for excellent cytogenetic analysis.

Conflict of interest

M.H. has an employment at DRG Instruments, Marburg, who redesigned the ELISA.

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany

    Esther Zipperer, Jochen G. Post, Andrea Kündgen, Frank Fox, Rainer Haas, Norbert Gattermann & Ulrich Germing

  2. DRG Instruments GmbH, Frauenbergstr. 18, 35039, Marburg, Germany

    Matthias Herkert

Authors
  1. Esther Zipperer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jochen G. Post
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Herkert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Kündgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frank Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rainer Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Norbert Gattermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ulrich Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther Zipperer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zipperer, E., Post, J.G., Herkert, M. et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol 92, 1617–1623 (2013). https://doi.org/10.1007/s00277-013-1839-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1839-5

Keywords

Search

Navigation